Pharmaceutical companies that are members of the Association of International Pharmaceutical Manufacturers (AIPM) spent 14.3 billion rubles in 2020 on payments to Russian specialists and healthcare organizations, as well as on research and development, FV reports together with MV. This is 11% less than in 2019, when the amount exceeded 16 billion rubles.
The publications analyzed the reports of 41 pharmaceutical companies. According to the data obtained, the amount of payments to doctors in 2020 decreased by 36%, from 3.9 billion rubles to 2.5 billion rubles. In 2019, the amount of payments in favor of doctors increased by 11% compared to 2018, when it was 3.5 billion rubles. As a result, the share of payments in the total amount of payments in favor of healthcare professionals decreased from 24% to 17%.
The cost of the valuables transferred in favor of healthcare organizations and in connection with research and development has also decreased, but the dynamics in this case is less dramatic compared to the same type of payments to doctors. Payments to healthcare organizations decreased by 7%, from 5.4 billion rubles in 2020 to 5 billion rubles. Research costs decreased by 1%, from RUB 6.9 billion to RUB 6.8 billion.
As a result, the shares of these two types of payments have increased. As a result, in 2020, research accounted for almost half of the payments, 48%. In 2019, they occupied 43%. The share of payments to organizations increased from 33% to 35%.
Among the doctors who disclosed individual data, only three people received more than a million rubles from pharmaceutical companies. These are Igor Tyurin, Doctor of Medical Sciences, Head of the Department of Radiology and Radiology of the Russian Medical Academy of Continuing Professional Education; Maxim Vyskub, employee of the State Autonomous Medical Institution “Medical Center” Cosmetology Clinic; and Dzhanashia Ketevan, specialist of OOO Ritz Medical. In 2019, 22 doctors received the corresponding amount. The average amount of payments among doctors who disclosed the data also decreased. In 2019, it was about 72,000 rubles, and last year, 47,000 rubles.
Pfizer became the most active company cooperating with doctors and healthcare organizations in 2020, having spent 1.3 billion rubles. A little more than a billion was transferred to the benefit of Russian healthcare by Sanofi. In 2019, four companies spent more than a billion rubles: Bayer, with 1.3 billion rubles, AstraZeneca, MSD and Janssen, with 1.2 billion rubles each.